Entecavir-based combination therapies for chronic hepatitis B

Luo, Aoran; Jiang, Xiaoyan; Ren, Hong

doi:10.1097/md.0000000000013596

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is an effective inhibitor of hepatitis B virus (HBV) replication and has minimal impact on liver function. However, it is also capable of transforming into an active tri-phosphate with the help of a phosphokinase (Sun et al 2016;Luo et al 2018). However, to date, few studies have examined the efficacy of microwave ablation and entecavir as a combination treatment for primary liver cancer.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of microwave ablation and entecavir as a combination treatment for primary liver cancer and their effects on hepatitis B virus and liver function

Zhang

Tan

et al. 2020

All Life

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of microwave ablation and entecavir as a combination treatment for primary liver cancer and their effects on hepatitis B virus and liver function

Zhang

Tan

et al. 2020

All Life

View full text Add to dashboard Cite

show abstract

Hepatitis B Virus and Hepatocellular Cancer: Molecular Mechanisms and Breakthroughs in Therapeutic Approaches

Sosa-Jurado,

Sedeño-Monge,

Márquez-Domínguez

et al. 2024

Pathogens Associated With the Development of Cancer in Humans

View full text Add to dashboard Cite

Effect of entecavir plus peginterferon α-2a on hepatitis B virus-RNA, IL-21 expression level, immune function and prognosis in patients with hepatitis B

et al. 2023

View full text Add to dashboard Cite

Combination of interferon and nucleotide analogues might be more effective in inhibiting replication of hepatitis B virus (HBV), thereby alleviating hepatic fibrosis and hepatocyte necrosis. Herein, we explored the impact of co-treatment of entecavir (ETV) and PEG-IFNα-2a on HBV-RNA, IL-21 level, immune function and prognosis in HBeAg-positive patients with low HBsAg level. Patients treated with ETV over 12 months received PEG-IFNα-2a treatment. Serum HBV markers and HBV-DNA were examined at 12, 24 and 48 weeks, and disappearance of HBsAg were measured at 24 weeks as an evaluation index for efficacy. Besides, levels of IL-21, serum albumin, and complement C3 were measured. During follow-up, we found that, HBsAg serological conversion appeared in 6.0% of all patients, with HBsAg disappearance in 18.1% and HBsAg <10 IU/mL in 10.8%. The HBeAg level in non-disappearing group was lower than HBsAg disappearing group (P <0.05) with AUC score of 0.720 for HBsAg suggested by HBeAg conversion rate (P <0.05). Of note, HBsAg levels decreased at 12 weeks of treatment (≥0.5 log IU/mL) and HBsAg was prone to disappearance (P <0.05). AUC of HBsAg disappearance predicted by the HBsAg levels at 12 weeks and 24 weeks were 0.810 (95% CI: 0.686–0.935, P = 0.000) and 0.842 (95% CI: 0.736–0.947, P = 0.000) compared with baseline. Combination of ETV and PEG-IFNα-2a resulted in enhancement of serum IL-21 level (210.803±72.477) and reduction of IL-21 expression (157.084±38.697). The IL-21 level was negatively correlated with immune function indicators serum albumin and serum complement C3. HBsAg conversion rate and early HBsAg changes are crucial to prediction of HBsAg disappearance. With ETV achieving great virological response, combination of ETV with PEG-IFNα-2a enhanced HBsAg loss, reducing IL-21 expression, and improving immune function in patients.

show abstract

Entecavir-based combination therapies for chronic hepatitis B

Abstract: Supplemental Digital Content is available in the text

Cited by 3 publications

References 29 publications

Efficacy of microwave ablation and entecavir as a combination treatment for primary liver cancer and their effects on hepatitis B virus and liver function

Efficacy of microwave ablation and entecavir as a combination treatment for primary liver cancer and their effects on hepatitis B virus and liver function

Hepatitis B Virus and Hepatocellular Cancer: Molecular Mechanisms and Breakthroughs in Therapeutic Approaches

Effect of entecavir plus peginterferon α-2a on hepatitis B virus-RNA, IL-21 expression level, immune function and prognosis in patients with hepatitis B

Contact Info

Product

Resources

About